

REMARKS


The above amendments have been made to place the application in a more traditional format.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached pages are captioned "**Version With Markings To Show Changes Made.**"

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____


Leonard C. Mitchard
Reg. No. 29,009

LCM:lks
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION

The paragraph beginning at page 33, line 15:

R(A/T)(A)LGX(I/V)(G/T)(N) (SEQ ID NO 39), or expressed as a consensus RXXLGXIXN (SEQ ID NO [40] 53), where X is any amino acid and amino acids in parentheses occur in more than 50% of known destruction sequences.

The paragraph beginning at page 34, line 26:

Some examples of ubiquitination recognition elements based on the N-recognin include;

Arg- ϵ Ahx-Cys

Arg- β -Ala- ϵ Ahx-Cys

Arg- ϵ Ahx- ϵ Ahx-Cys

Phe- ϵ Ahx-Cys

Phe- β -Ala- ϵ Ahx-Cys

Phe- ϵ Ahx- ϵ Ahx-Cys

Arg-Ala- ϵ Ahx-Cys

Arg-Ala- β -Ala- ϵ Ahx-Cys (SEQ ID NO:66)

Arg-Ala- ϵ Ahx- ϵ Ahx-Cys

The paragraph beginning at page 35, line 1:

Phe-Ala-ε Ahx-Cys

Phe-Ala-β-Ala-ε Ahx-Cys (SEQ ID NO:67)

Phe-Ala-ε Ahx-ε Ahx-Cys

The paragraph beginning at page 37, line 1:

R(A/T)(A)LGX(I/V)(G/T)(N) (SEQ ID NO 39), or expressed as a consensus RXXLGXIXN (SEQ ID NO [40] 53), where X is any amino acid and amino acids in parentheses occur in more than 50% of known destruction sequences.

The paragraph beginning at page 58, line 1:

motif CCXXCC (SEQ ID NO:47) and WEAAAREACCRECCARA (SEQ ID NO 48), and AEAAAREACCRECCARA (SEQ ID NO 49), is 4',5'-bis(1,3,2-dithioarsolan-2-yl)fluorescein with other bis-organoarsenical being useful (Griffin BA, 1998, Science 218, 269, which is hereby incorporated by reference in its entirety).

The paragraph beginning at page 60, line 19:

Control of protein levels in the liver of a transgenic organism

An example of the above embodiment is the demonstration of targeted ubiquitination to mediate quantitative and tissue specific control of gene expression in transgenic mice. The expression vector was

constructed using the luciferase gene and a liver specific promoter ~ the promoter of the liver-enriched activator protein driving the expression of the luciferase gene (Kistner A., 1996, Proc. Natl. Acad. Sci. 93, 10933-10938). The luciferase gene was engineered to contain the AEAAAREACCRECCARA (SEQ ID NO [40] 49), sequence at the C terminus using synthetic oligonucleotides and PCR based

Please replace the paragraph beginning at page 73, line 14, with the following rewritten paragraph:

FOIA b 7 - D

Further ubiquitination recognition elements are synthesized as follows using methods described above.

1. Arg-Ala- ϵ Ahx-Cys
2. Arg-Ala- β -Ala- ϵ Ahx-Cys (SEQ ID NO:66)
3. Arg-Ala- ϵ Ahx- ϵ Ahx-Cys
4. Phe-Ala- ϵ Ahx-Cys
5. Phe-Ala- β -Ala- ϵ Ahx-Cys (SEQ ID NO:67)
6. Phe-Ala- ϵ Ahx- ϵ Ahx-Cys

IN THE CLAIMS

13. (Amended) A compound as in claim 1 wherein said ubiquitination recognition element contains a moiety selected from the group consisting of Arg- ϵ Ahx-Cys, Arg- β -Ala- ϵ Ahx-Cys, Arg- ϵ Ahx- ϵ Ahx-Cys, Phe- ϵ Ahx-Cys, Phe- β -Ala- ϵ Ahx-Cys, Phe- ϵ Ahx- ϵ Ahx-Cys, Arg-Ala- ϵ Ahx-Cys, Arg-Ala- β -Ala- ϵ Ahx-Cys (SEQ ID NO:66), Arg-Ala- ϵ Ahx- ϵ Ahx-Cys, Phe-Ala- ϵ Ahx-Cys, Phe-Ala- β -Ala- ϵ Ahx-Cys (SEQ ID NO:67) and Phe-Ala- ϵ Ahx- ϵ Ahx-Cys.